Used in the treatment of B-cell non-Hodgkin’s lymphoma, this antibody targets CD20 antigen on B cells, leading to their depletion through mechanisms like antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. It is employed as a reference standard in biosimilar development and analytical studies to ensure consistency and efficacy in therapeutic antibody production. Its well-characterized profile supports comparative studies in immunotherapy research and quality control in biopharmaceutical manufacturing.